CompletedPhase 1NCT03383614
Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
Studying Filariasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Drugs for Neglected Diseases
- Principal Investigator
- Jeremy Dennison, PhD MBChBHammersmith Medicines Research Limited
- Intervention
- LSF emodepside (BAY 44-4400) or matching placebo(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18-45 years · MALE
- Timeline
- 2017 – 2018
Study locations (1)
- Hammersmith Medicines Research Limited, London, United Kingdom
Collaborators
Bayer · Bill and Melinda Gates Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03383614 on ClinicalTrials.govOther trials for Filariasis
Additional recruiting or active studies for the same condition.